- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Roche to provide HIV diagnostic solutions to Global Fund
18 June 2015 • Author: Victoria White
This marks a further step in the collaboration between Roche and the Global Fund, an organisation that has pioneered providing effective and economic solutions for healthcare to achieve the best results for patients.
“We are proud to be chosen as a supplier for the Global Fund and to continue to provide reliable HIV-1 diagnostics where they are needed most,” said Paul Brown, Head of Roche Molecular Diagnostics. “Leveraging our vast number of systems already installed around the world and continuing to work with organisations such as the Global Fund, we expand our commitment to healthcare solutions which make a real difference in those regions most impacted by HIV.”
Framework agreement with Global Fund strengthens access to HIV diagnostics
The HIV-1 tests eligible for the Global Fund collaboration utilise a unique dual-target design to simultaneously amplify and detect two separate regions of the HIV-1 genome which are not subject to selective drug pressure. This innovative, fully-automated solution will provide reliable results for laboratories and physicians to more confidently and efficiently treat HIV-1 patients undergoing therapy. For early infant diagnostics, the dual-target HIV-1 qualitative test v2.02 works with both plasma and dried blood spot (DBS) collection cards, eliminates the need for refrigeration, drastically reduces the volume of blood required and makes sample collection and transportation easy even from the smallest infant in the most rural area.
In 2014, Roche announced the Global Access Programme in partnership with the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Clinton Health Access Initiative (CHAI), the President’s Emergency Plan For AIDS Relief (PEPFAR) and the Global Fund to fight AIDS, TB and Malaria. With this programme, Roche continues its commitment towards the UNAIDS 90-90-90 goals and an AIDS-free generation.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics